The company expects to recruit around 10 patients in the trial with an aim to establish the response rate to the therapy.
The trial is intended to evaluate the safety, anti-tumor effect and bioactivity of infusion of patients’ own T cells that have been genetically modified to express a high affinity T cell receptor (TCR) specific for a type of tumor antigen (protein) known as a cancer testis antigen (CT antigen).
The secondary endpoints are to investigate the persistence of the genetically modified cells and to perform analyses of the anti-tumor immune responses in patients.
The company is planning to open the second site later this year at Washington University, St. Louis, Missouri.
Adaptimmune CEO said James Noble said this is the third trial we are running with this TCR and if they show enhanced responses in this trial, they envisage broadening their scope to a wider spectrum of sarcomas.